Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIYA-BMT01: Probiotic-Supplemented Gut Decontamination in Allogeneic HSCT
jRCTs051240081Recruiting
- Sponsor
- Japan Society for the Promotion of Science
- Start
- Jul 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in Acute Leukaemia, myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD) and 2 more comparing CBM588 administration group with Placebo group (2 arms). Primary endpoint: Change in gut microbiota alpha diversity (Shannon index) at day 14 post-transplant. Started Jul 2024; status: recruiting.
02
Drugs
clostridium butyricum
03
Conditions
Acute Leukaemiamyelodysplastic syndrome (MDS)myeloproliferative disorder (MPD)lymphosarcomahematopoietic malignancies
Beyond the preview
Go deeper on jRCTs051240081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240081.